UNITY Biotechnology Announces Improvement In Visual Acuity Sustained Through 24 Weeks Following Single Dose Of UBX1325 In Phase 1 Study Of Patients With Advanced Vascular Eye Disease

by | Nov 9, 2021 | Uncategorized | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.